Abstract
Authors' Reply to Wang et al., "Comment on 'Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial'".
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have